کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
6190533 1257383 2014 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Systematic review of combination therapies for mycosis fungoides
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی تومور شناسی
پیش نمایش صفحه اول مقاله
Systematic review of combination therapies for mycosis fungoides
چکیده انگلیسی


- Only few drug combination trials in mycosis fungoides have a high level of evidence.
- Addition of interferon-α or retinoids to PUVA does not enhance the response rate.
- Addition of methotrexate to interferon-α may increase the response rate.
- Combination of bexarotene with vorinostat or gemcitabine is not recommendable.

BackgroundA variety of therapeutic options are available for mycosis fungoides, the most prevalent subtype of cutaneous T cell lymphomas, but thus far, no regimen has been proven to be curative. A combination of treatments is a well-established strategy to increase the therapeutic efficacy. However, data from clinical trials analyzing such combinations for the treatment of mycosis fungoides are scarce.ObjectiveTo analyze the available evidence on combination therapies with emphasis on the combination of psoralen with UVA phototherapy (PUVA), interferon-alpha and bexarotene with another treatment.MethodsSystematic literature review of the databases Embase, Cochrane, Medline, and Medline in Process.ResultsCombination of PUVA with interferon-alpha or retinoids did not result in an increased overall response rate. Addition of methotrexate but not retinoids to interferon-alpha may increase the overall response rate. Bexarotene was investigated in one trial each with vorinostat, methotrexate or gemcitabine, whereby only methotrexate possibly enhanced the effect of bexarotene.ConclusionFor mycosis fungoides, no combination treatment has been demonstrated to be superior to monotherapy. Based on our analysis, we conclude that in certain clinical situations, patients may benefit from a combination of PUVA with interferon-alpha or a retinoid or a combination of the latter two. Furthermore, patients in advanced stages may benefit from the combination of methotrexate and interferon-alpha or bexarotene. Finally, the combination of bexarotene with either vorinostat or gemcitabine did not increase the overall response rate but resulted in more pronounced side effects and cannot be recommended.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Cancer Treatment Reviews - Volume 40, Issue 8, September 2014, Pages 927-933
نویسندگان
, , , , ,